^
    Back
    Association details:
    Biomarker:EGFR exon 20 insertion
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Rybrevant (amivantamab-vmjw) (EGFR inhibitor, c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/21/2023
    Excerpt:
    Non-Small Cell Lung Cancer: EGFR Exon 20 Insertion Mutation…Subsequent therapy...Amivantamab-vmjw + carboplatin + pemetrexed (nonsquamous)...
    Secondary therapy:
    carboplatin + pemetrexed
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Title:

    RYBREVANT® (amivantamab) in combination with chemotherapy is the first therapy approved by the European Commission for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations

    Excerpt:
    ...European Commission (EC) has approved a Type II variation for RYBREVANT®(amivantamab) in combination with chemotherapy (carboplatin and pemetrexed) for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

    Excerpt:
    ...- Participant must have histologically or cytologically confirmed, locally advanced or metastatic, nonsquamous non-small cell lung cancer (NSCLC) with documented primary epidermal growth factor receptor (EGFR) Exon 20ins activating mutation...
    Trial ID:
    PAPILLON